SciELO - Scientific Electronic Library Online

 
vol.133 número7Adición de un cortocircuito arterio-venoso durante el soporte vital extracorpóreo veno-arterial de un paciente con síndrome cardiopulmonar por Hantavirus: Caso clínicoLa globalización en la educación superior europea. Pródromos para nuestra educación médica: The precursor of changes in Chilean medical education índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Revista médica de Chile

versão impressa ISSN 0034-9887

Resumo

LARIS E, María del Rosario; ARTEAGA L, Antonio; CUEVAS M, Ada  e  RIGOTTI R, Attilio. HDL cholesterol: A new target in the treatment of lipid disorders and atherosclerosis?. Rev. méd. Chile [online]. 2005, vol.133, n.7, pp.823-832. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872005000700011.

Low plasma HDL cholesterol levels are an independent risk factor for atherosclerotic cardiovascular disease. During the past years, the study of HDL has been stimulated by the discovery of novel genes and proteins, which have provided new insights into the molecular and cellular mechanisms involved in HDL metabolism. In addition, recent clinical studies focused on treating low HDL as primary objective in high cardiovascular risk patients have been very encouraging. Furthermore, new drugs for raising HDL cholesterol are under development. This article reviews the recent progress in the HDL field and its important implications for the pathophysiology and treatment of atherosclerosis. In the near future, we expect that new drugs with specific and beneficial effects on HDL metabolism and the associated cardiovascular risk should improve the current approach to this disease with high burden on health systems and society

Palavras-chave : Atherosclerosis; Cardiovascular diseases; Lipoproteins, HDL cholesterol.

        · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons